literature

HBV mutation literature information.

[The drug resistance mutation detection and relevant factors analysis of HBV P region in chronic hepatitis B patients in Weifang City, Shandong Province].

PMID: 25997324 2015 Bing du xue bao

Abstract: M204V/I mutation mostly existed in the form of joint L180M mutation, the mutation rate was age-related.

Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection.

PMID: 25982306 2015 The Brazilian journal of infectious diseases

Abstract: Of these, nine and eight patients carried lamivudine (LAM)-/telbivudine (LdT)-resistance mutations (rtL180M, rtM204I/V) and adefovir (ADV)-resistance mutations (rtA181T/V, rtN236T), respectively.

Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Cote d'Ivoire.

PMID: 25852125 2015 Antiviral therapy

Abstract: Among 11/127 (8.7%) patients with high-level persistent viraemia (last HBV VL: >=10(5) copies/ml), only two harboured incident LAM-resistance mutations at positions rtV173L+rtL180M+rtM204V with no patient exhibiting TDF/FTC-resistance.

Characterization of novel entecavir resistance mutations.

PMID: 25817219 2015 Journal of hepatology

Abstract: RESULTS: RtI163V and rtA186T mutations were detected together with LAMr (rtL180M and rtM204V) at VBT.

New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.

PMID: 25732900 2015 Journal of medical virology

Abstract: Classical lamivudine resistance mutations (rtM204V/rtL180M) were present in one naive-treatment patient infected with genotype G.

Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.

PMID: 25712861 2015 Journal of medical virology

Abstract: No patient showed mutations that conferred resistance against lamivudine (L180M, M204V/I), adefovir (A181T, N236S), or entecavir (I169M, A184T/V, S202I/G, M250V/I/L).

High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.

PMID: 25654813 2015 Antiviral therapy

Abstract: Three major patterns of mutations in HBV polymerase gene, namely single (rtM204V), double (rtL180M+rtM204V) and triple (rtV173L+rtL180M+rtM204V) mutations, are associated with 3TC-resistance; additionally, the triple mutation has vaccine-escape potential due to a corresponding change in overlapping surface gene.

Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.

PMID: 25287170 2015 Gut and liver

Abstract: The baseline mutation profiles, rtM204I (p=0.992), rtM204I/V (p=0.177), and rtL180

Discussion: Furthermore, rtL180M mutations were newly emerged in four patients as minor population at 48 weeks of LAM-ADV combination therapy but they were restored as baseline mutation profile at 96 weeks.

Discussion: In the present study, baseline rtL180M was not associated with cumulative virological response.

Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.

PMID: 24992206 2015 Antiviral therapy

Abstract: Clonal sequencing identified 13 drug-resistant HBV strains: rtL80I+M204I, rtL80I+M204V, rtL180M+M204I, rtL180M+M204V, rtM204I, rtM204V, rtL80I+L180M+M204I, rtL80I+L180M+

Molecular epidemiology and genotyping of hepatitis B virus of HBsAg-positive patients in Oman.

PMID: 24835494 2014 PloS one

Abstract: Especially the lamivudine resistance mutations rtL180M/rtM204V and rtM204I were detected.

Discussion: Besides other previously described resistance mutations, the best-described drug resistance mutations are the LAM resistance mutations rtL180M and rtM204V/I and the adefovir resistance mutations rtA181V/T and rtN236T.

Browser Board

Co-occurred Entities

Filtrator